We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-10.29%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$501M
AUM Growth
+$25.6M
Cap. Flow
+$93.2M
Cap. Flow %
18.6%
Top 10 Hldgs %
66.14%
Holding
135
New
29
Increased
35
Reduced
10
Closed
61

Top Buys

Rank Stock Value
1
ICUI icon
ICU Medical
ICUI
+$5.87M
2
INSP icon
Inspire Medical Systems
INSP
+$5.07M
3
GH icon
Guardant Health
GH
+$4.07M
4
SIBN icon
SI-BONE Inc
SIBN
+$4.06M
5
NSTG
NanoString Technologies, Inc.
NSTG
+$3.8M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$8.34M
2
MDT icon
Medtronic
MDT
+$7.57M
3
AZTA icon
Azenta
AZTA
+$5.7M
4
CNC icon
Centene
CNC
+$5.49M
5
ZBH icon
Zimmer Biomet
ZBH
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 28.11%
2 Industrials 0.17%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
76
PUT
Amarin Corp
AMRN
$296M
– –
-10,000
Closed -$3.25M
ARAY icon
77
CALL
Accuray
ARAY
$34.6M
– –
-250,000
Closed -$1.13M
ARVN icon
78
Arvinas
ARVN
$588M
– –
-75,000
Closed -$1.26M
AXDX
79
CALL
DELISTED
Accelerate Diagnostics
AXDX
– –
-7,000
Closed -$1.61M
AZN icon
80
CALL
AstraZeneca
AZN
$246B
– –
-50,000
Closed -$3.96M
AZTA icon
81
Azenta
AZTA
$1.54B
– –
-162,676
Closed -$5.7M
BCRX icon
82
BioCryst Pharmaceuticals
BCRX
$2.64B
– –
-101,245
Closed -$773K
CLLS
83
Cellectis
CLLS
$291M
– –
-35,437
Closed -$1M
CLSD
84
DELISTED
Clearside Biomedical
CLSD
– –
-3,375
Closed -$311K
CNC icon
85
Centene
CNC
$32.1B
– –
-75,810
Closed -$5.49M
DXCM icon
86
CALL
DexCom
DXCM
$33.8B
– –
-200,000
Closed -$7.15M
EHC icon
87
PUT
Encompass Health
EHC
$12.4B
– –
-62,850
Closed -$3.9M
ELAN icon
88
Elanco Animal Health
ELAN
$11.4B
– –
-100,000
Closed -$3.49M
FOLD
89
DELISTED
Amicus Therapeutics
FOLD
– –
-45,560
Closed -$551K
GMED icon
90
Globus Medical
GMED
$11.4B
– –
-57,500
Closed -$3.26M
ICUI icon
91
CALL
ICU Medical
ICUI
$4.55B
– –
-32,000
Closed -$9.05M
LAB icon
92
CALL
Standard BioTools
LAB
$309M
– –
-150,000
Closed -$1.12M
LIVN icon
93
CALL
LivaNova
LIVN
$4.33B
– –
-210,000
Closed -$26M
LLY icon
94
CALL
Eli Lilly
LLY
$1.08T
– –
-25,000
Closed -$2.68M
MDGL icon
95
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-3,702
Closed -$793K
MDT icon
96
Medtronic
MDT
$116B
– –
-81,027
Closed -$7.57M
NTRA icon
97
Natera
NTRA
$45.1B
– –
-70,871
Closed -$1.7M
NVO
98
CALL
Novo Nordisk
NVO
$207B
– –
-400,000
Closed -$9.43M
OCUL icon
99
Ocular Therapeutix
OCUL
$2.14B
– –
-86,058
Closed -$592K
OMCL icon
100
PUT
Omnicell
OMCL
$1.68B
– –
-50,000
Closed -$3.6M
2 3
4
5 6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2018 Portfolio in Review

As of Q4 2018, Pura Vida Investments held 135 positions worth $501M, up 5.4% from $475M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Pura Vida Investments deployed $93.2M of net new capital in Q4 2018, opening 29 new positions and adding to 35 existing holdings. Its largest new stake was Guardant Health: 110,363 shares worth $4.15M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 35% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Boston Scientific, an estimated $8.34M trimmed.

  • Pura Vida Investments's largest Q4 2018 buy was Guardant Health: 110,363 shares worth $4.15M.
  • Pura Vida Investments added most to ICU Medical in Q4 2018, an estimated $5.87M increase.
  • Pura Vida Investments's biggest Q4 2018 reduction was Boston Scientific, cutting an estimated $8.34M.
  • Pura Vida Investments fully exited Medtronic in Q4 2018, selling an estimated $7.57M.
  • Pura Vida Investments's ten largest holdings make up 66% of its $501M portfolio in Q4 2018.
  • Pura Vida Investments opened 29 new positions and closed 61 in Q4 2018.
  • Pura Vida Investments's portfolio value rose 5.4% quarter-over-quarter to $501M.

Based on Pura Vida Investments's 13F filing for Q4 2018, filed 14 Feb 2019.